Antares PharmaInc (NASDAQ:ATRS) Marks Movement With Q4 And Patent Troll

818

Dallas, Texas 03/19/2014 (FINANCIALSTRENDS) –  Antares PharmaInc (NASDAQ:ATRS) which is just celebrating its better-than-expected fourth quarter results and full year financial results, has fallen into a legal hassle, with Chicago-based  Medac Pharma Inc, a subsidiary of Germany-based medacGesellschaftfürklinischeSpezialpräparatembH filing a patent violation.

The issue is related to a recently approved patent for – methotrexate, which also contains Autopen.

Medac as holders of US Patent 8,664,231, called as ‘concentrated Methotrexate Solutions’ assumes superior rights to supply, use distribute and sell methotrexate as of march 4, 2014.

Antares PharmaInc (NASDAQ:ATRS) has received approval from the Food and Drug Administration to market OTREXUP, a trademark drug which is used as an injection to treat multiple forms of rheumatoid arthritis, psoriasis, as well aspolyarticular idiopathic arthritis in children. It has commenced marketing of the same as of January 15, 2014, with the help of marketing group LEO Pharma.

Medac Pharm has meanwhile sought financial compensation from the courts for the infringed copyrights and sale of Otrexup in the US by Antares PharmaInc (NASDAQ:ATRS). Atres and LEO Pharma are yet to offer a response on the issue.

Fourth quarter saw positive news

The fourth quarter for this drug maker proved to be good quarter as it held forth on two counts – first, the launch of the rheumatoid drug for arthritis –Otrexup; the second factor were the positive results for Phase 2 trials for a testosterone drug the company produces- VibexQuickShot.

Antares PharmaInc (NASDAQ:ATRS) had at the end of the second week of February reported that the phase 2 trials for its testosterone injector-VibexQuickShot-had achieved required levels for the drug, to proceed to the next phase. The study was conducted on a group of 29 patients. This has been a good start in 2014 for ATRS as the market value for a testosterone – replacement market has been $2.8 billion, as per sales recorded in 2013.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.